GeneNews Limited

GeneNews Limited

November 10, 2011 08:30 ET

GeneNews' Sentinel Principle® Used to Discover New Blood Based Biomarkers for Nasopharyngeal Carcinoma

TORONTO, ONTARIO--(Marketwire - Nov. 10, 2011) - GeneNews Limited (TSX:GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that a presentation entitled "Nasopharyngeal Carcinoma Biomarkers derived using Peripheral Blood Transcriptome" was given today at the 2011 Asia Pacific Cancer Conference, Kuala Lumpur, Malaysia.

Nasopharyngeal carcinoma ("NPC") is a common cancer in certain parts of Northern Africa and Southern China. The presentation reported on the application of GeneNews' proprietary Sentinel Principle® platform technology to 278 peripheral whole blood samples collected from NPC patients, non-NPC cancer patients and unaffected controls. The study reported the identification of blood-based biomarkers that distinguished NPC patients from controls and from patients with other cancers with high accuracy.

"Of the genes coding for this signature, the top five performers are known to be involved in carcinoma of the head and neck, tumor-associated antigens, and/or genes involved in cellular signaling. This investigation is the first to use whole blood from NPC patients to analyze genome-wide expression patterns. In addition to distinguishing NPC patients from non-NPC patients, we were able to identify blood-based biomarkers that may be able to predict which patients are more likely to respond to treatment. These findings, therefore, have significant clinical implications with respect to optimizing therapy for NPC patients," commented principal investigator and lead author, Dato' Dr. Adel Zaatar, Senior Consultant Radiotherapist & Oncologist, Mount Miriam Cancer Hospital, Penang, Malaysia.

"As demonstrated by this study, the applications of our proprietary platform technology, the Sentinel Principle®, continue to expand rapidly," said Gailina J. Liew, President and Chief Operating Officer of GeneNews.

The Sentinel Principle®, a platform technology discovered and developed by GeneNews, is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the constant and dynamic physiological interaction of blood with the cells, tissues and organs of the human body. This technology is the basis of GeneNews' initial product, ColonSentry™, the world's first blood test for colorectal cancer, and the SentinelGx™ suite of services. GeneNews' broad global patent portfolio includes issued foundational patents and pending patents in diverse disease areas such as cancer, cardiovascular, neurological and inflammatory conditions.

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. For more information on GeneNews and ColonSentry™, visit or

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

Contact Information